Distribution of saposin proteins (sphingolipid activator proteins) in lysosomal storage and other diseases

(Tay-Sachs disease/Sandhoff disease/fucosidosis/Gaucher disease/Niemann-Pick disease)

SATOSHI MORIMOTO*, YOSHIMI YAMAMOTO[†], JOHN S. O'BRIEN[‡], AND YASUO KISHIMOTO

Department of Neurosciences and Center for Molecular Genetics, University of California, San Diego, La Jolla, CA 92093

Communicated by Morris E. Friedkin, January 22, 1990 (received for review November 27, 1989)

Saposins (A, B, C, and D) are small glycopro-ABSTRACT teins required for the hydrolysis of sphingolipids by specific lysosomal hydrolases. Concentrations of these saposins in brain, liver, and spleen from normal humans as well as patients with lysosomal storage disease were determined. A quantitative HPLC method was used for saposin A, C, and D and a stimulation assay was used for saposin B. In normal tissues, saposin D was the most abundant of the four saposins. Massive accumulations of saposins, especially saposin A (about 80-fold increase over normal), were found in brain of patients with Tay-Sachs disease or infantile Sandhoff disease. In spleen of adult patients with Gaucher disease, saposin A and D accumulations (60- and 17-fold, respectively, over normal) were higher than that of saposin C (about 16-fold over normal). Similar massive accumulations of saposins A and D were found in liver of patients with fucosidosis (about 70- and 20-fold, respectively, over normal). Saposin D was the primary saposin stored in the liver of a patient with Niemann-Pick disease (about 30-fold over normal). Moderate increases of saposins B and D were found in a patient with GM1 gangliosidosis. Normal or near normal levels of all saposins were found in patients with Krabbe disease. metachromatic leukodystrophy, Fabry disease, adrenoleukodystrophy, I-cell disease, mucopolysaccharidosis types 2 and 3B, or Jansky-Bielschowsky disease. The implications of the storage of saposins in these diseases are discussed.

Sphingolipid activator proteins are small glycoproteins required for the maximal hydrolysis of sphingolipids by specific lysosomal hydrolases. Sphingolipid activator protein 1 discovered in 1964 (1) (herein termed saposin B) activates the hydrolysis of cerebroside sulfate, GM1 ganglioside, and globotriaosylceramide by arylsulfatase A, acid β -galactosidase, and α -galactosidase, respectively (2-5), and also appears to promote hydrolysis of a variety of other lipids including glycerolipids (6). A second activator protein, discovered in 1971 (7), sphingolipid activator protein 2 (herein termed saposin C) activates the hydrolysis of glucosylceramide and galactosylceramide by β -glucosylceramidase (EC 3.2.1.45) and galactosylceramide β -galactosidase (EC 3.2.1.46), respectively (8). Saposin C acts differently than saposin B since it interacts with the above enzymes increasing their maximal velocity and decreasing their Michaelis constant (9-11), whereas saposin B binds lipid substrates solubilizing them for hydrolysis. A third activator protein termed sphingolipid activator protein 3, also known as GM2 activator, is a specific activator for the hydrolysis of ganglioside GM2 by GM2 β -N-acetylgalactosaminidase (12, 13). Sphingolipid activator protein 3 is genetically distinct and unrelated to the saposins studied here.

The two remaining saposin proteins, saposins A and D, were discovered (16) in 1989 after the cDNA encoding them

was analyzed. Studies of the proteolytic processing of saposins B and C showed that both are initially biosynthesized as a large molecular mass precursor (70 kDa) that, after proteolytic processing, generates the 12-kDa saposin proteins (14, 15). This laboratory cloned a cDNA for saposins B and C and showed that a common precursor generates both polypeptides (16). O'Brien *et al.* (16) and Collard *et al.* (17) proposed that two additional activator proteins similar in structure to saposins B and C are generated by proteolysis of the same precursor, which we call prosaposin.

Fürst *et al.* (18) obtained protein sequencing data on a polypeptide that they isolated. After comparison with nucleotide sequences (16), they came to the conclusion that a common precursor gives rise to three activator proteins, saposins B and C and the third protein that they isolated and called component C located within the carboxyl-terminal portion of the precursor; they did not identify saposin A.

We isolated saposin D from the spleen of a patient with Gaucher disease, purified it to homogeneity, determined that it had the same amino acid sequence as component C, and demonstrated that it was a specific activator of sphingomyelinase (19). Similar to saposin C, saposin D appears to exert its effect upon the enzyme and did not bind sphingomyelin. We also isolated the fourth potential saposin, called saposin A, from the spleen of a patient with Gaucher disease, purified it to homogeneity, and demonstrated that saposin A, like saposin C, is a specific activator of β -glucosylceramidase and galactosylceramide β -galactosidase (20). Saposin A, like saposins C and D, activates by binding to these enzymes not to lipid substrates. Presented in Fig. 1 is the nomenclature we proposed for this family of proteins (Fig. 1).

Inui and Wenger (21) reported that saposin B accumulated in tissues of patients with lysosomal storage diseases, especially tissue from patients with infantile GM1 gangliosidosis. The accumulation of saposin C in the spleen of patients with Gaucher disease has been known since its discovery (7). In the present report we describe the tissue distributions and concentrations of saposins A, B, C, and D in lysosomal storage and other diseases. Massive accumulations, especially of saposin A, were found in brain of patients with Tay-Sachs disease or Sandhoff disease and in liver of patients with fucosidosis and accumulations of saposin D were found in patients with Niemann-Pick disease.

MATERIALS AND METHODS

Human Tissues. Human tissues used in this study were collected over many years and stored at -20° C in this laboratory. Diagnoses were made by pathological examination, analysis of storage material, and enzyme assays for the ap-

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "*advertisement*" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

^{*}Present address: Faculty of Pharmaceutical Sciences, Kyushu, University, Fukuoka 812, Japan.

[†]Present address: Department of Biology, Hamamatsu University, School of Medicine, Hamamatsu. Shizuoka, 431-31, Japan. [‡]To whom reprint requests should be addressed.

ſ								$\overline{\Lambda}$]-
1	60	143	195	275	311	390 4	05	487	524
L									
				1					
	Ĺ		L		L				
	2	2		3		4	5		

FIG. 1. Nomenclature of saposin proteins. Prosaposin, the precursor of saposins A, B, C, and D, is shown as a bar with the positions of the four saposins crosshatched. Locations of peptides are indicated by brackets. Brackets: 1, prosaposin (residues 1–524); 2, saposin A (residues 60–143); 3, saposin B (residues 195–275); 4, saposin C (residues 311–390); 5, saposin D (residues 405–487).

propriately deficient enzyme. Each disease listed is accompanied by its appropriate number as assigned by McKusick (22).

Determination of Saposin A, B, C, and D. Amounts of individual saposins were determined by a method to be described elsewhere. Individual human tissues (0.4-3.8 g)were homogenized in water and the homogenates were boiled and centrifuged. The concentrations of saposins A, C, and D in the supernatant were determined by two consecutive HPLC separations. The boiled extract was first fractionated on a C_4 reversed-phase column with an acetonitrile gradient. After the impurities were eluted, saposins A, C, and D were eluted together at high acetonitrile concentrations and this fraction was then analyzed by an anion-exchange HPLC using NaCl gradient. Saposins D, A, and C were eluted from the column in individual peaks and quantitated by measuring peak areas. Saposin B was quantified by determining its stimulative activity on pure human liver GM1 ganglioside β -galactosidase.

RESULTS

The saposin content in the brain, liver, and spleen of 5 normal individuals and 33 patients with lysosomal storage disease were analyzed. The results are presented in Table 1.

Saposins in Normal Humans. Three brains, four livers, and three spleens were available from normal adults (20-50 years). Tissues were obtained at autopsy and were free of pathology by gross and microscopic examination. Brain contained 15 \pm 5 μ g (mean \pm SD) of saposin A per g (dry tissue), $14 \pm 11 \ \mu g$ of saposin B per g, $15 \pm 5 \ \mu g$ of saposin C per g, and $47 \pm 11 \,\mu$ g of saposin D per g, with a total saposin content of 92 \pm 14 μ g/g. Normal liver contained 25 \pm 5, 21 \pm 9, 30 \pm 17, and 49 \pm 26 μ g of saposins A, B, C, and D per g, respectively, with a total saposin content of $125 \pm 46 \,\mu g/g$ and normal spleen contained 27 ± 15 , 34 ± 12 , 27 ± 11 , and $77 \pm 11 \ \mu g$ of saposins A, B, C, and D, per g, respectively, with a total saposin content of $165 \pm 61 \,\mu g/g$. Thus, among normal tissues examined, spleen contained the highest saposin content followed by liver and brain. In each tissue, saposin D was the most abundant saposin.

Saposins in GM2 Gangliosidosis. One unexpected finding was massive accumulation of saposins in brain from patients with either Tay–Sachs disease or Sandhoff disease. The three patients with Tay–Sachs disease expired at 3, 4, and 5 years of age. In each patient, brain had the highest saposin content, 2501 to 2753 μ g/g, a 27- to 30-fold increase above normal. Approximately one-half of this increase was due to saposin A, which averaged 88 times normal. When gray matter was separated from white matter about 4-fold higher concentrations of saposins were detected in the former than the latter.

A similar large increase in brain, particularly of saposins A and C, was also found in patients with Sandhoff disease. On the other hand, no such increase was seen in brain from patients with adult or juvenile type GM2 gangliosidosis. In brain extracts from a Sandhoff disease patient or a Tay–Sachs disease patient, an extra peak with retention time 15.4 min appeared after the saposin A peak on anion-exchange HPLC. Western blot of the peak after SDS/PAGE revealed that it is an unknown derivative of saposin A (data not shown).

Saposins in Gaucher Disease. Saposin C was first isolated and found to accumulate in spleen from patients with adult Gaucher disease (7). Our investigation disclosed that this saposin is not the most abundant saposin accumulating. In the four spleens examined total saposin ranged from 3267 to $3652 \mu g/g$ (dry weight), a 20- to 22-fold increase above normal; about one-half of the increase was due to saposin A, which accumulated to levels averaging 60 times normal. Saposin C was elevated 17 times normal, saposin D was 16 times normal, and saposin B was 5 times normal. Saposins did not accumulate in the brain of two patients with infantile Gaucher disease.

Saposins in GM1 Gangliosidosis. Saposin B has been shown to accumulate in the liver of patients with infantile GM1 gangliosidosis (21). Our examination of liver from two such patients showed that saposin D accumulated to nearly the same extent as saposin B (about 8 times normal). In juvenile GM1 gangliosidosis a smaller increase in saposin B was found in liver and a somewhat larger increase in saposins A and C was found in brain.

Saposins in Fucosidosis. In patients with fucosidosis, massive accumulations of saposins A and D were found in liver. In one patient saposin A accumulated to levels 102 times normal whereas saposin D was about 23 times normal. Accumulations of saposins B and C were less significant (7to 17-fold increase). Accumulations of saposins in spleen and brain were modest.

In the brain from one fucosidosis patient, an extra peak (retention time 11.6 min) was observed after anion-exchange HPLC. Samples of this unknown peak were collected after anion-exchange HPLC for further analysis. It was found that this peak comprised two components with retention times of 56.0 and 59.6 min after hydrophobic HPLC. Neither component stimulated β -glucosidase activity but each cross-reacted with anti-saposin D antibodies on a Western dot blot. After treatment with neuraminidase from *Clostridium per-fringers* (Boehringer Mannheim) both peaks shifted on anion-exchange HPLC to two peaks (8.6 and 9.0 min) identical to the peaks of saposin D (data not shown). Therefore, it was concluded that these two compounds are sialylated derivatives of saposin D. The value for saposin D presented in Table 1 includes these derivatives.

Saposins in Niemann-Pick Disease. In two patients with infantile Niemann-Pick disease, the predominant saposin accumulating was saposin D. In liver the accumulation was 31 and 24 times normal and in one spleen a 19-fold increase was found. Smaller accumulations of other saposins were found in liver and spleen, and in brain the accumulation of saposins was minimal.

Saposins in Other Diseases. Elevation of saposin concentrations, if present, were small in brain, liver, and spleen of patients with Krabbe disease, mucopolysaccharidosis II and III, or Jansky-Bielschowsky late infantile lipidosis. No increase of saposins were found in liver and spleen of a patient with Fabry disease, in brains from two patients with adrenoleukodystrophy, in brain of a patient with Alzheimer disease in an area with numerous neuritic plaques, in brain and spleen of a patient with I-cell disease, or in brain and liver of a patient with late infantile metachromatic leukodystrophy.

DISCUSSION

Prosaposin is proteolytically processed to generate saposins A, B, C, and D by cleavage at lysine or arginine residues at the boundaries of each saposin domain generating equimolar quantities of saposins A, B, C, and D (Fig. 1). Saposin D is 2-3 times more abundant than saposins A, B, and C in most

Table 1. Saposin tissue distribution

Source Tissue A B C D Total Source Tissue A B C D Tens W Brain 9 14 16 34 73 M Brain 99 128 32 207 456 Liver 29 23 59 92 203 Liver 275 255 217 1126 4393 M Brain 15 0 21 61 97 G Liver 95 55 56 160 179 229 50 156 160 179 229 14 160 150 Nicenan-Pick disease type 41 150 155 142 211 14 163 225 14 166 130 23 141 120 131 120 131 1498 295 133 141 130 142 271 140 203 141 203 142 117 112				Saposin, $\mu g/g$ (dry weight)						Saposin, $\mu g/g$ (dry weight)				
Normal tissues Fuccosidosi (type 2) (23:000) U Brain 9 14 16 34 73 M Brain 89 12.8 22 203 59 92 203 Liver 295 21.7 11.26 4393 M Brain 15 0 21 61 97 G Liver 295 21.7 11.26 4393 Y Liver 30 44 20 31 115 Spleen 22.2 17 18 27.8 12.9 21.17 11.26 27.8 12.9 21.17 12.0 73 43 205 75.9<	Source	Tissue	A	В	С	D	Total	Source	Tissue	A	В	С	D	Tota
U Brain 9 14 16 34 73 M Brain 80 128 32 207 458 Liver 29 23 99 92 203 Liver 2754 295 217 1126 4393 Spleen 42 51 41 116 200 Spleen 221 34 20 431 Spleen 31 29 26 50 136 Nieman-Pick disease type A (infantile) (25720) Y Liver 12 166 143 48 146 613 438 A-14 Brain 122 28 9 47 105 Elver 213 511 1498 295 M Brain 1395 168 444 59 262 9 47 105 Liver 4217 535 642 1174 203 M Brain 1395 168 244 933 250 Brain 21 11 19 109 160 Liver 90 <th< td=""><td></td><td></td><td>Normal</td><td>tissues</td><td></td><td></td><td></td><td></td><td>Fuco</td><td>sidosis (ty</td><td>pe 2) (2</td><td>3000)</td><td></td><td></td></th<>			Normal	tissues					Fuco	sidosis (ty	pe 2) (2	3000)		
Liver 29 23 59 92 203 Liver 275 217 1126 4393 M Brain 15 0 21 61 97 G Liver 99 376 516 1009 292 Liver 19 9 23 47 80 15 Spleen 124 221 34 136 515 Spleen 31 29 26 50 136 Neman-Fick disses type A (infantle) (2720) 523 A:10 Liver 122 166 61 99 2 84 140 535 542 117 128 71 433 A:14 Drain 125 186 444 599 2623 Infantle Krabe disease (2450) 17 123 714 123 140 235 542 17 135 542 174 235 217 140 235 542 174 235 542 174 243 243 243 243 243 243 243 243 243 </td <td>U</td> <td>Brain</td> <td>9</td> <td>14</td> <td>16</td> <td>34</td> <td>73</td> <td>М</td> <td>Brain</td> <td>89</td> <td>128</td> <td>32</td> <td>207</td> <td>456</td>	U	Brain	9	14	16	34	73	М	Brain	89	128	32	207	456
Spleen 42 51 41 116 270 Spleen 27 28 52 162 1203 M Brain 15 0 115 Spleen 124 221 34 136 Spleen 124 221 34 136 Spleen 127 2 14 136 Spleen 128 227 136 136 Nieman-Pick disease type A (infantile) (1737) 131 148 239 A-101 Liver 12 12 14 66 109 S Brain 135 66 143 458 A-14 Brain 1355 186 444 599 2623 Infantil Kribbed disease (2420) 113 21 11 21 13 21 140 219 34 2401 135 66 140 217 262 141 19 100 141 13 101 101 101 101 101 101 101 101 101 </td <td></td> <td>Liver</td> <td>29</td> <td>23</td> <td>59</td> <td>92</td> <td>203</td> <td></td> <td>Liver</td> <td>2754</td> <td>295</td> <td>217</td> <td>1126</td> <td>4393</td>		Liver	29	23	59	92	203		Liver	2754	295	217	1126	4393
M Brain 15 0 21 61 97 G Liver 99 37.6 51.6 107 229 Spleen 31 29 26 50 136 Niemann-Pick disease type A (infantile) (23720) A-101 Liver 19 9 23 47 98 F Brain 110 40 60 207 159 623 A-101 Liver 22 28 9 47 150 Liver 108 401 64 149 247 596 544 263 1174 263 A-14 Brain 1395 186 445 597 1 Brain 217 21 71 123 Liver 85 190 376 81 337 J Brain 32 17 21 71 133 24 104 219 11 19 109 106 104 219 11 19 109 106 104 23 114 123 11 19 109 106		Spleen	42	51	41	116	250		Spleen	262	728	52	162	1205
Liver 30 34 20 31 11 Spleen 12 22 24 43 36 57 Y Liver 19 9 23 47 98 F Brain 152 106 207 159 623 A-101 Liver 22 17 18 27 84 Liver 237 531 1498 2395 Spleen 7 22 17 18 27 84 Liver 237 536 42 114 428 A-14 Brain 1305 186 444 599 2623 Liver 40 13 27 140 249 M Brain 110 186 441 509 2501 Liver 40 13 27 14 81 19 Spleen 276 82 154 415 927 10 389 897 Brain 11 19 100 56 Spleen 107 64 210 336 82 140	Μ	Brain	15	0	21	61	97	G	Liver	959	376	516	1079	2929
Spleen31292650136Nieman-Pick disease type A (infantile) (25720)A-101Liver2217182784Liver2813753149829623A-101Brain2228947105Brain110440166143458A-14Brain2228947105Liver45135564211742623Tay-Sachs diseaeC27280)TSpleen616143458566445971516277127103217140219Liver8562193332501Brain321712711313198090071001614024750684193551641392713141919109160160Liver8017072521103832501Mtcooplysaccharidosis II (Hunter Hisease) (2090)58585811411719109160160142355841575167450352164133484Mtcooplysaccharidosis II (Hunter Hisease) (2090)58311611611611616614035161611661403516161166163116176160 <td< td=""><td></td><td>Liver</td><td>30</td><td>34</td><td>20</td><td>31</td><td>115</td><td></td><td>Spleen</td><td>124</td><td>221</td><td>34</td><td>136</td><td>515</td></td<>		Liver	30	34	20	31	115		Spleen	124	221	34	136	515
Y Liver 19 9 23 47 98 F Brain 121 106 207 159 623 A-101 Liver 122 14 66 109 S Brain 101 40 166 143 458 A-14 Brain 122 28 9 47 105 Liver 128 124 263 Tay-Sach disease C12280) 9 44 599 2623 Infantie Krabbe disease 71 12 71 133 53 542 17 12 71 133 53 59 42 219 111 19 90 160 10 140 129 11 19 109 160 11 19 109 160 11 19 109 160 13 27 140 219 13 11 19 140 13 27 140 219 16 11 19 19 16 100 16 110 100 160 110 100 160 10		Spleen	31 29 26 50 136			Niemann-Pick disease type A (infantile) (25720)								
A-101 Liver 22 17 18 27 84 Liver 28 137 531 1498 295 Spleen 7 22 28 9 47 105 Spleen 614 247 596 944 2623 Tay-Sachs disease (27280) Tay-Sachs disease (27280) Spleen 614 247 596 944 2401 M Brain 1395 186 444 599 2623 Infantile Krabed disease (24200) 12 71 13 27 14 623 Liver 87 68 154 455 992 201 Spleen 70 24 81 179 140 219 Liver 90 170 64 170 494 Mucooplyacachardossi II (Hunter disease) (3990) 160 160 109 160 Spleen 207 252 110 388 97 8 241 903 Spleen 141 179 170 172 637 351 141 179 170 172 160	Y	Liver	19	9	23	47	98	F	Brain	152	106	207	159	623
A:14 Brain 7 22 14 66 109 S Brain 101 40 166 143 458 A:14 Brain 1395 122 28 9 47 105 Liver 451 555 642 2401 M Brain 1395 186 444 599 2623 Infantile Krabbe disease (24520) Liver 86 22 9 181 337 J Brain 32 17 12 71 13 Spleen 276 82 154 410 189 333 201 Spleen 47 72 24 81 179 Liver 90 170 64 170 494 Mucopolysaccharidosis II (Hunter disease) (30900) 109 160 160 170 421 170 472 48 36 82 149 350 Spleen 115 35 91 77 186 241 903 35 64 252 234 450 100 50 102	A-101	Liver	22	17	18	27	84		Liver	228	137	531	1498	2395
A-14 Brain 22 28 9 47 105 Liver 451 355 642 1174 2623 M Brain 1395 186 444 599 2623 Infantile Krabbe disease (24520) 11 13 27 140 219 L Brain 1410 189 519 383 2501 Spleen 47 77 14 219 L Brain 1410 189 519 383 2501 Spleen 47 77 24 81 179 197 472 Liver 90 170 64 170 494 Mucopolysaccharidosis II (Hunter disease) (30990) 462 Spleen 207 252 110 388 957 B Brain 21 11 19 160 366 Liver 473 53 541 903 54 240 169 262 24 40 36 52 22 24 450 55 56 32 59 57 167 360		Spleen	7	22	14	66	109	S	Brain	110	40	166	143	458
	A-14	Brain	22	28	9	47	105		Liver	451	355	642	1174	2623
M Brain 1395 186 444 599 2623 Infantile Krabe disease (24520) Liver 85 22 49 181 337 J Brain 32 17 12 71 133 Spleen 276 82 154 415 927 Liver 40 13 27 140 219 Liver 90 170 64 170 494 Mucoopolysaccharidosis II (Hunter disease) (3090) 17 133 27 140 219 Spleen 207 252 110 388 957 B Brain 11 19 109 160 Spleen 122 438 523 644 2758 Liver 88 36 82 149 356 White matter 476 -* 572 697 281 A Liver 142 50 70 167 360 Spleen 242 104 153 34 834 Mucopolysaccharidosis II (Sanfilipot type B) (25292) 135 55 155 150<		Tay-	Sachs dis	sease (2'	7280)				Spleen	614	247	596	944	2401
Liver 85 22 49 181 337 J Brain 32 17 12 71 133 Spleen 276 82 154 415 927 Liver 40 13 27 140 219 Spleen 47 27 24 81 179 Muccoplysaccharidosis II (Hunter disease (13090) S Total brain 1152 438 523 644 2758 Total brain 1152 438 523 644 2758 Total brain 1152 438 523 644 2758 Total brain 1152 438 -572 697 2851 A Liver 88 36 82 149 356 Gray matter 1583 -* 572 697 2851 A Liver 142 80 70 169 462 Liver 99 31 65 140 336 Spleen 123 -* 70 167 360 Spleen 242 104 153 334 834 Muccoplysaccharidosis II (Sanflinpo type B) (25292) Adult GM2 gangliosidosis (2780) Liver 78 72 46 136 322 Spleen 133 277 97 152 658 Liver 78 74 6 15 86 224 Liver 87 46 15 86 224 Liver 100 56 83 120 359 Spleen 133 277 97 152 658 R Brain 53 9 48 55 155 Liver 87 46 15 86 224 Liver 20 41 135 97 279 Spleen 247 19 55 347 909 Spleen 124 59 166 236 133 Spleen 123 -* 35 54 385 1978 Adrenoleucotystrophy (30010) 	Μ	Brain	1395	186	444	599	2623		Infanti	le Krabbe	disease	(24520)		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Liver	85	22	49	181	337	J	Brain	32	17	12	71	133
L Brain 1410 189 519 383 2501 Spleen 47 27 24 81 179 Liver 90 170 64 170 494 Mucopolysaccharidosis II (Hunter disease) (30990) Spleen 207 252 110 388 957 B Brain 21 11 19 109 160 Spleen 476 * 186 241 903 Spleen 123 7 70 167 360 Spleen 123 * 70 167 360 Spleen 123 * 70 162 450 Liver 99 31 65 140 336 324 Mucopolysaccharidosis III (Sanflippo type B) (25292) 450 A Brain 115 35 91 73 18 Liver 104 123 52 234 450 105 360 Liver 78 72 46 136 332 Spleen 133 277 97 152 658 120		Spleen	276	82	154	415	927		Liver	40	13	27	140	219
	L	Brain	1410	189	519	383	2501		Spleen	47	27	24	81	179
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Liver	90	170	64	170	494		Mucopolysacch	aridosis II	(Hunter	r disease	:) (30990)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Spleen	207	252	110	388	957	В	Brain	21	11	19	109	160
White matter Gray matter (Gray matter (186)-*186 572241 697903 2851ALiver Liver144 70570169 462 460472 472 472 470Gray matter (Gray matter Liver99 242104153 153334834Liver D141 23-*70167 360Adult GM2 gangliosidosis (27280)DBrain 115111 3551 5177318Liver D106233224 52450ABrain Liver78 727246 46332Spleen 133133 277277 9797152 56858 50 515Liver Liver78 7472 4646 1586 234234Liver Liver20 4141 1359 48 4855 515Liver Liver Adult Gaucher disease (23080)70 47256 44210 56566 562Spleen 548 515135 5483652 517A Brain 16 2718 18 518135 567NSpleen Spleen 1602103 203662118 5623652 578A Brain 16 27 1818 88 118118 18 20100NSpleen Spleen 1602103 203652 662A 660104 27 1818 88 118117 117 11814 23 2319 251117 117 117NSpleen 1602103 203652 203169 20332 	S	Total brain	1152	438	523	644	2758		Liver	88	36	82	149	356
Gray matter 1583 -* 572 697 2851 A Liver 142 80 70 169 462 Liver 99 31 65 140 336 Spleen 123 * 70 167 360 Spleen 242 104 153 334 834 Mucopolysacharidosis III (Sanfilipo Vipe B) (25292) Adult GM2 gangliosidosis (27280) D Brain 141 23 52 234 450 Liver 78 91 77 318 Liver 100 56 83 120 359 Liver 78 24 61 36 256 R Brain 515 515 Liver 87 84 55 88 Brain 59 166 263 613 Jinfantile Sandhoff disease (24800) 54 42 110 566 Spleen 54 69 127 255 506 Spleen 287 119 155 347 909 Spleen 54 69 12		White matter	476	_*	186	241	903		Spleen	144	51	79	197	472
		Gray matter	1583	_*	572	697	2851	Α	Liver	142	80	70	169	462
Spleen 242 104 153 334 834 Mucopolysaccharidosis III (Sanfilippo type B) (25292) A Brain 115 35 91 77 318 Liver 100 56 83 120 359 A Brain 115 35 91 77 318 Liver 100 56 83 120 359 Liver 78 72 46 136 332 Spleen 133 277 97 152 658 Juvenile GM2 gangliosidosis (23071) Juvenile GM2 gangliosidosis (23071) Juvenile GM2 gangliosidosis (23071) Juvenile GM2 gangliosidosis (230450) Juvenile GM2 gangliosidosis (23071) Juvenile GM2 gangliosidosis (23071) Juvenile GM2 gangliosidosis (23050) R Brain 53 9 48 55 155 Liver 87 46 15 86 234 Liver 20 41 135 97 293 Spleen 287 119 155 347 909 Spleen 136 63 135 356 Spleen 160 203		Liver	99	31	65	140	336		Spleen	123	*	70	167	360
Adult GM2 gangliosidosis (27280) D Brain 141 23 52 23 450 A Brain 115 35 91 77 318 Liver 100 56 83 120 359 Liver 78 46 135 97 48 55 155 Juser 100 56 83 120 20450 20450		Spleen	242	104	153	334	834		Mucopolysacchar	idosis III (Sanfilip	po type	B) (25292)
A Brain 115 35 91 77 318 Liver 100 56 83 120 59 Liver 78 72 46 136 332 Spleen 133 277 97 152 658 Juvenile GM2 gangliosidosis (23071) Jansky-Bielschowsky (late infantile lipidosis) (20450) Jansky-Bielschowsky (late infantile lipidosis) (20450) Liver 87 46 15 86 234 Liver 20 41 135 97 293 Spleen 350 64 42 110 56 8 379 90 86 63 135 356 Spleen 287 119 155 347 90 Spleen 54 69 127 25 566 R Brain 91 55 548 385 1978 Adrenoleucodystrophy (30010) 117 Adult Gaucher disease (23080) B Brain 16 27 18 58 118 N Spleen 1602 203 662 1185 3652 <		Adult GN	M2 gangli	osidosis	(27280)			D	Brain	141	23	52	234	450
Liver 78 72 46 136 332 Spleen 133 277 97 152 658 Juvenile GM2 gangliosidosis (23071) Jansky-Bielschowsky (late infantile lipidosis) (20450) Jansky-Bielschowsky (late infantile lipidosis) (20450) L Brain 96 28 46 86 256 R Brain 53 9 48 55 155 Liver 87 46 10 566 Spleen 124 59 166 263 613 Infantile Sandhoff disease (26880) Infantile Sandhoff disease (26880) Fabry disease (30150) Fabry disease (30150) Fabry disease (30150) Fabry disease (30150) H Brain 1097 119 155 347 909 Spleen 54 69 127 255 506 R Brain 91 55 548 385 1978 Adrenoleucodystrophy (30010) Adrenoleucodystrophy (30010) Fabry disease (210430) 117 M Spleen 1602 203 662 1185 3652 A Brain 16 27 18	Α	Brain	115	35	91	77	318		Liver	100	56	83	120	359
Juvenile GM2 gangliosidosis (23071) Jansky-Bielschowsky (late infantile lipidosis) (20450) L Brain 96 28 46 86 256 R Brain 53 9 48 55 155 Liver 87 46 15 86 234 Liver 20 41 135 97 293 Spleen 350 64 42 110 566 Spleen 124 59 166 263 613 H Brain 1097 119 427 460 2103 W Liver 49 108 63 135 356 Spleen 187 119 55 548 385 1978 Adrenoleucodystrophy (30010)		Liver	78	72	46	-136	332		Spleen	133	277	97	152	658
L Brain 96 28 46 86 256 R Brain 53 9 48 55 155 Liver 87 46 15 86 234 Liver 20 41 135 97 293 Spleen 350 64 42 110 566 Spleen 124 59 166 263 613 Infantile Sandhoff disease (26880) Fabry disease (30150) Fabry disease (30150) Fabry disease (30150) Fabry disease (30160) 72 255 506 R Brain 991 55 548 385 1978 Adrenoleucodystrophy (30010) Adrenoleucodystrophy (30010) Adult Gaucher disease (23080) B Brain 16 27 18 58 118 N Spleen 1602 203 662 1185 3652 A Brain 14 23 19 61 117 M Spleen 153 235 685 1069 3522 Alzheimer disease (25250) I-cell disease (25250) I-cell disease (25250) I		Juvenile GM2 gangliosidosis (23071)							Jansky–Bielschowsky (late infantile lipidosis) (20450)					
Liver 87 46 15 86 234 Liver 20 41 135 97 293 Spleen 350 64 42 110 566 Spleen 124 59 166 263 613 Infantile Sandhoff disease (2680) Fabry disease (30150) H Brain 1097 119 427 460 2103 W Liver 49 108 63 135 356 Spleen 287 119 155 347 909 Spleen 54 69 127 255 506 R Brain 991 55 548 385 1978 Adrenoleucodystrophy (30010) Adult Gaucher disease (23080) B Brain 16 27 18 58 118 N Spleen 1602 203 662 1185 3652 A Brain 14 23 19 61 117 M Spleen 1533 235 685 1069 3522 Alzheimer disease (10430) T Spleen 1604 103 479 1474 3660 N Brain 39 -* 35 57 131 H Spleen 1472 124 488 1184 3267 I-cell disease (25250) Infantile Gaucher disease (23090) G Brain 3 28 7 15 53 A Brain 19 34 9 21 83 Spleen 33 34 72 139 278 Z Brain 16 19 5 10 50 Late infantile metachromatic leucodystrophy (25010) Infantile GMI gangliosidosis (23050) P Brain 20 20 110 187 337 B Liver 136 410 177 359 1082 Liver 136 410 177 359 1082 Liver 136 410 177 359 1082 J Brain 260 79 186 158 679 Liver 93 118 186 266 662 Spleen 182 96 286 292 856 L Brain 326 24 73 196 619 Liver 186 195 257 491 1129 W Brain 353 77 189 184 802	L	Brain	96	28	46	86	256	R	Brain	53	9	48	55	155
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		Liver	87	46	15	86	234		Liver	20	41	135	97	293
Fabry disease (30150) Fabry disease (30150) H Brain 1097 119 427 460 2103 W Liver 49 108 63 135 356 Spleen 287 119 125 347 909 Spleen 54 69 127 255 50 R Brain 991 55 548 385 1978 Adrenoleucodystrophy (30010) Adrenoleucodystrophy (30010) Adult Gaucher disease (23080) B Brain 16 27 18 58 118 N Spleen 1602 203 662 1185 3652 A Brain 14 23 19 61 117 M Spleen 1602 203 662 1185 3652 A Brain 14 23 19 61 117 M Spleen 1602 203 652 N Brain 39 * 35 57 131 H Spleen 1472 124 488 <t< td=""><td></td><td>Spleen</td><td>350</td><td>64</td><td>42</td><td>110</td><td>566</td><td></td><td>Spleen</td><td>124</td><td>59</td><td>166</td><td>263</td><td>613</td></t<>		Spleen	350	64	42	110	566		Spleen	124	59	166	263	613
H Brain 1097 119 427 460 2103 W Liver 49 108 63 135 356 Spleen 287 119 155 347 909 Spleen 54 69 127 255 506 R Brain 991 55 548 385 1978 Adrenoleucodystrophy (30010) Adult Gaucher disease (23080) B Brain 16 27 18 58 118 N Spleen 1602 203 662 1185 3652 A Brain 14 23 19 61 117 M Spleen 1604 103 479 1474 3660 N Brain 39 -* 35 57 131 H Spleen 1472 124 488 1184 3267 I-cell disease (25250) Infantile Gaucher disease (23090) G Brain 3 28 7 15 53 Z Brain 16 19 5 10 50 Late infantile metachrom		Infantile	Sandhoff	disease	(26880)				Fa	abry disea	se (3015	0)		
Spleen 287 119 155 347 909 Spleen 54 69 127 255 506 R Brain 991 55 548 385 1978 Adrenoleucodystrophy (30010)	Н	Brain	1097	119	427	460	2103	W	Liver	49	108	63	135	356
R Brain 991 55 548 385 1978 Adrenoleucodystrophy (30010) Adult Gaucher disease (23080) B Brain 16 27 18 58 118 N Spleen 1602 203 662 1185 3652 A Brain 16 27 18 58 118 M Spleen 1602 203 662 1185 3652 A Brain 14 23 19 61 117 M Spleen 1604 103 479 1474 3660 N Brain 39 * 35 57 131 H Spleen 1472 124 488 1184 3267 I-cell disease (25250) I-cell disease (25250) Infantile Gaucher disease (23050) P Brain 30 34 72 139 278 Z Brain 16 19 5 10 D Late infantile metachromatic leucodystrophy (25010) Infantile GM1 gangliosidosis (23050) P Brain 20 110 187 </td <td></td> <td>Spleen</td> <td>287</td> <td>119</td> <td>155</td> <td>347</td> <td>909</td> <td></td> <td>Spleen</td> <td>54</td> <td>69</td> <td>127</td> <td>255</td> <td>506</td>		Spleen	287	119	155	347	909		Spleen	54	69	127	255	506
Adult Gaucher disease (23080) B Brain 16 27 18 58 118 N Spleen 1602 203 662 1185 3652 A Brain 14 23 19 61 117 M Spleen 1533 235 685 1069 3522 Alzheimer disease (10430) 1 T Spleen 1604 103 479 1474 3660 N Brain 39 * 35 57 131 H Spleen 1472 124 488 1184 3267 I-cell disease (25250) * 35 57 131 H Spleen 1472 124 488 1184 3267 -Icell disease (25250) * 33 34 72 139 278 Z Brain 16 19 5 10 50 Late infantile metachromatic leucodystrophy (25010)	R	Brain	991	991 55		548 385			Adrenoleucodystrophy (3001		30010)			
N Spleen 1602 203 662 1185 3652 A Brain 14 23 19 61 117 M Spleen 1533 235 685 1069 3522 Alzheimer disease (10430) Alzheimer disease (10430) T Spleen 1604 103 479 1474 3660 N Brain 39 * 35 57 131 H Spleen 1472 124 488 1184 3267 I-cell disease (25250) I-cell disease (25250) I 57 131 M Brain 19 34 9 21 83 Spleen 33 34 72 139 278 A Brain 16 19 5 10 50 Late infantile metachromatic leucodystrophy (25010) Infantile GM1 gangliosidosis (23050) P Brain 20 20 110 187 337 Juverile GM1 gangliosidosis (23060) I 1428 1137 Iver 111 32 60 341 544 Liver 182		Adult Gaucher disease (23080)						В	Brain	16	27	18	58	118
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Ν	Spleen	1602	203	662	1185	3652	Α	Brain	14	23	19	61	117
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	М	Spleen	1533	235	685	1069	3522		Alzł	eimer dise	ease (10	430)		
HSpleen 1472 124 488 1184 3267 I-cell disease (25250)Infantile Gaucher disease (23090)GBrain3 28 7 15 53 ABrain19 34 9 21 83 Spleen 33 34 72 139 278 ZBrain161951050Late infantile metachromatic leucodystrophy (25010)Infantile GM1 gangliosidosis (23050)PBrain 20 20 110 187 337 BLiver136 410 177 359 1082 Liver 111 32 60 341 544 WLiver190 287 231 428 1137 Liver 111 32 60 341 544 JBrain 260 79 182 158 679 Liver 111 32 60 341 544 ULiver93 118 186 266 662 59 577 491 1129 WBrain 353 77 189 184 802 500 500 500 500 500	Т	Spleen	1604	103	479	1474	. 3660	Ν	Brain	39	*	35	57	131
Infantile Gaucher disease (23090) G Brain 3 28 7 15 53 A Brain 19 34 9 21 83 Spleen 33 34 72 139 278 Z Brain 16 19 5 10 50 Late infantile metachromatic leucodystrophy (25010) Infantile GM1 gangliosidosis (23050) P Brain 20 20 110 187 337 B Liver 136 410 177 359 1082 Liver 111 32 60 341 544 W Liver 190 287 231 428 1137 Liver 111 32 60 341 544 W Liver 190 287 231 428 1137 Liver 111 32 60 341 544 J Brain 260 79 182 158 679 Liver 131 32 60 341 544 Liver 93 118 186 266	Н	Spleen	124	488	1184	3267		I-	cell diseas	e (25250))			
A Brain 19 34 9 21 83 Spleen 33 34 72 139 278 Z Brain 16 19 5 10 50 Late infantile metachromatic leucodystrophy (25010) Infantile GM1 gangliosidosis (23050) P Brain 20 20 110 187 337 B Liver 136 410 177 359 1082 Liver 111 32 60 341 544 W Liver 190 287 231 428 1137 Liver 111 32 60 341 544 W Liver 190 287 231 428 1137 Liver 111 32 60 341 544 J Brain 260 79 182 158 679 Liver 93 118 186 266 662 59 Liver 136 1129 129 129 129 129 129 129 129 129 129 129 129 129 </td <td></td> <td>Infantile</td> <td>Gaucher</td> <td>disease</td> <td>(23090)</td> <td></td> <td></td> <td>G</td> <td>Brain</td> <td>3</td> <td>28</td> <td>7</td> <td>15</td> <td>53</td>		Infantile	Gaucher	disease	(23090)			G	Brain	3	28	7	15	53
Z Brain 16 19 5 10 50 Late infantile metachromatic leucodystrophy (25010) Infantile GM1 gangliosidosis (23050) P Brain 20 20 110 187 337 B Liver 136 410 177 359 1082 Liver 111 32 60 341 544 W Liver 190 287 231 428 1137 Juvenile GM1 gangliosidosis (23060) Juvenile GM1 gangliosidosi	Α	Brain	19	34	9	21	83		Spleen	33	34	72	139	278
Infantile GM1 gangliosidosis (23050) P Brain 20 20 110 187 337 B Liver 136 410 177 359 1082 Liver 111 32 60 341 544 W Liver 190 287 231 428 1137 Juvenile GM1 gangliosidosis (23060) Juvenile GM1 gangliosidosis (23060)	Z	Brain	16	19	5	10	50		Late infantile met	achromati	c leucod	lystroph	y (25010)	
B Liver 136 410 177 359 1082 Liver 111 32 60 341 544 W Liver 190 287 231 428 1137 Juvenile GM1 gangliosidosis (23060) Juvenile GM1 gangliosidosis (23060) Juvenile GM1 gangliosidosis (23060) Juvenile GM1 182 158 679 Juvenile GM1 Juvenile GM2 Select Select<		Infantile G	M1 gangli	iosidosi	s (23050)			Р	Brain	20	20	110	187	337
WLiver1902872314281137Juvenile GM1 gangliosidosis (23060)JBrain26079182158679Liver93118186266662Spleen18296286292856LBrain3262473196619Liver1861952574911129WBrain35377189184802	В	Liver	136	410	177	359	1082		Liver	111	32	60	341	544
Juvenile GM1 gangliosidosis (23060) J Brain 260 79 182 158 679 Liver 93 118 186 266 662 Spleen 182 96 286 292 856 L Brain 326 24 73 196 619 Liver 186 195 257 491 1129 W Brain 353 77 189 184 802	W	Liver 190 287 231 428 1137												
J Brain 260 79 182 158 679 Liver 93 118 186 266 662 Spleen 182 96 286 292 856 L Brain 326 24 73 196 619 Liver 186 195 257 491 1129 W Brain 353 77 189 184 802	-	Juvenile G	M1 gangli	osidosis	s (23060)		·							
Liver93118186266662Spleen18296286292856LBrain3262473196619Liver1861952574911129WBrain35377189184802	J	Brain	260	79	182	158	679							
Spleen 182 96 286 292 856 L Brain 326 24 73 196 619 Liver 186 195 257 491 1129 W Brain 353 77 189 184 802		Liver	93	118	186	266	662							
L Brain 326 24 73 196 619 Liver 186 195 257 491 1129 W Brain 353 77 189 184 802		Spleen	182	96	286	292	856							
Liver 186 195 257 491 1129 W Brain 353 77 189 184 802	L	Brain	326	24	73	196	619							
W Brain 353 77 189 184 802		Liver	186	195	257	491	1129							
	w	Brain	555	11	189	184	802		· · · · · · · · · · · · · · · · · · ·					

Values can be converted to molar quantities using the known molecular masses of each (saposins B, C, D, 12 kDa; saposin A, 16 kDa). Numbers in parentheses are from ref. 22.

*Undetectable.

normal tissues studied, which may suggest a slower degradation rate for saposin D than for saposins A, B, and C.

In Tay-Sachs disease and Sandhoff disease a massive accumulation of GM2 ganglioside occurs in neurons secondary to β -N-acetylhexosaminidase deficiency (13). The accumulation of saposins especially saposin A (about 80 times normal) is in the same range as that of GM2 ganglioside, although the actual quantities of the protein are lower than the ganglioside by about an order of magnitude. It is known that in lysosomal storage diseases activities of lysosomal enzymes are generally increased (except for that of the deficient enzyme) but these increases are rarely higher than 3 times normal. In tissues where GM2 ganglioside does not accumulate such as in liver and spleen and in later onset GM2 gangliosidosis where GM2 accumulation in brain is smaller, saposin A concentrations were much lower, indicating parallel storage of ganglioside GM2 and saposin A. In attempting to understand this coincident association we determined the effect of saposin A on *in vitro* hydrolysis of ganglioside GM2 by GM2 β -N-acetyl-galactosaminidase and no stimulation was observed (20). Their concomitant storage may imply a complex between ganglioside GM2 and saposin A. Since ganglioside GM2 accumulates predominantly within lysosomal storage granules called cytoplasmic membranous bodies in neurons in patients with Tay–Sachs disease (23), saposin A may be similarly localized. Previous analyses of the cytoplasmic granules stored in Tay–Sachs disease (24) have indicated that the isolated granules contained about 10% protein on a weight basis. The actual content may be higher since leaching out of protein could have occurred during isolation of the granules. It will be of interest to determine whether the protein portion of cytoplasmic membranous bodies comprises saposins, especially saposin A.

It is also necessary to determine whether saposins play any role in the neurological deterioration that occurs in Tay-Sachs disease. The massive quantities that are stored are large enough to implicate them in the neuronal pathology. From studies in man (25) and in experimental animals with GM1 and GM2 gangliosidosis (26), neurological deterioration and symptomatology are best correlated with alterations of neuronal membrane morphology including proliferation of growth-cone-associated neurites from the axon hillock (secondary neurites) and the presence of bizarre swellings (meganeurites) interposed between the soma and the initial segment of the axon. The relationship between ganglioside accumulation and these distortions of neuronal structure is unclear. Similar membranous neuronal changes have been documented in feline mannosidosis in which gangliosides do not accumulate (27). Unfortunately, we did not have access to brain tissue from feline mannosidosis to determine saposin concentrations. The relationship between saposin accumulations and aberrant neuronal structure should be explored especially since neurological deterioration is directly correlated with the morphologic changes.

In infantile Sandhoff disease, storage of GM2 ganglioside in brain is quantitatively similar to that in Tay-Sachs disease (except that asialo-GM2 also accumulates) (13) and similar massive accumulations of saposin A were present. Asialo-GM2 and globoside are stored in spleen in Sandhoff disease, but ganglioside GM2 concentrations are insignificant and saposin concentrations are not large (2-3 times normal in spleen) pointing to neuronal ganglioside GM2 storage as the predominant feature accompanying saposin A accumulation. Another unexpected finding was the very large accumulation of saposins A and D in spleen of patients with adult Gaucher disease. It had been noted (7) that saposin C accumulates in the spleen of patients with Gaucher disease but our results demonstrate that saposins D and A accumulate to levels many times higher. Although these saposins do not form a complex with glucocerebroside, their accumulation in the spleen of patients with Gaucher disease indicate that saposins may undergo an uncharacterized association with either increased glucocerebroside or mutated glucosylceramide β glucosidase, as suggested by Datta and Radin (28). They reported increase of saposin C in mouse tissues after injection of glucocerebroside or of an inactivator of glucosidase. They also reported that the uptake of β -glucosylceramidase by neuroblastoma cells was enhanced by adding saposin C (29). The role of saposins A and D in the pathophysiology of the glucocerebroside storage in Gaucher disease is worthy of study, especially since saposin A is now known to be a second activator of β -glucosylceramidase (20). Glucocerebroside storage in brain of patients with infantile Gaucher disease is much less than in liver and saposin concentrations were much lower therein in accord with the proposed association of saposins and glucocerebroside.

The accumulation of saposins A and D in liver of patients with fucosidosis was also unexpected. We have demon-

strated (20) that neither saposin A nor C stimulates α -L-fucosidase activity using a synthetic α -L-fucoside substrate (4-methylumbelliferyl α -L-fucoside) but no studies were conducted using fucoglycolipids as substrates. Accumulations of saposins A and D were much smaller in the brain and since neutral fucoglycolipids are not stored in brain of patients with fucosidosis, the parallel storage of fucoglycolipid and saposins A and D may indicate a complex between these lipids and saposins. Experiments to explore the role of saposins A and D in fucoglycolipid hydrolysis are clearly warranted.

We reported (19) that saposin D was a specific sphingomyelinase activator. However, the degree of stimulation was lower than that of β -glucosylceramidase by saposin A or C (20), perhaps because our sphingomyelinase preparation was only partially purified whereas our preparations of β glucosylceramidase were highly purified. The fact that saposin D is the major saposin accumulating in liver and spleen of patients with Niemann-Pick disease where sphingomyelin is massively stored is in keeping with the *in vitro* studies, suggesting that saposin D activates the lysosomal hydrolysis of sphingomyelin (19).

Insignificant accumulations of saposins were found in demyelinating disorders such as metachromatic leucodystrophy, Krabbe disease, and adrenoleucodystrophy even though storage of sphingolipids, such as cerebroside sulfate in metachromatic leucodystrophy, occurs in white matter. Normal quantities were found in I-cell disease, Alzheimer disease, and Jansky-Bielschowsky late infantile lipidosis. The failure to detect significant accumulations of saposins in visceral tissues from a patient with Fabry disease is surprising, especially since saposin B is reported to stimulate the hydrolysis of the galactosphingolipids stored in Fabry disease by α -galactosidase (4). Normal saposin concentrations were also found in liver from patients with Hunter disease or Sanfilippo disease type B, even though large accumulations of mucopolysaccharides occur within hepatic lysosomes.

We are grateful to Ms. Susan O'Brien for her assistance in the preparation of this manuscript. Support for this research was provided by Grants NS-08682 and HD-18983 to J.S.O. and NS-13559 to Y.K. from the National Institutes of Health.

- 1. Mehl, E. & Jatzkewitz, H. (1964) Hoppe-Seylers Z. Physiol. Chem. 339, 260-276.
- Fischer, G. & Jatzkewitz, H. (1978) Biochim. Biophys. Acta 528, 69-76.
- Li, S.-C., Kihara, H., Serizawa, S., Li, Y.-T., Fluharty, A. L., Mayes, J. S. & Shapiro, L. J. (1985) J. Biol. Chem. 260, 1867-1871.
- Li, S.-C., Wan, C.-C., Mazzotta, M. Y. & Li, Y.-T. (1974) Carbohydr. Res. 34, 189-193.
- Wenger, D. A. & Inui, K. (1984) in Molecular Basis of Lysosomal Storage Disorders, eds. Brady, R. O. & Barranger, J. A. (Academic, New York), pp. 1–18.
- Li, S.-C., Sonnino, S., Tettamanti, G. & Li, Y.-T. (1988) J. Biol. Chem. 263, 6588-6591.
- Ho, M.-W. & O'Brien, J. S. (1971) Proc. Natl. Acad. Sci. USA 68, 2810–2813.
- 8. Wenger, D. A., Sattler, M. & Roth, S. (1982) Biochim. Biophys. Acta 712, 639-649.
- 9. Berent, S. L. & Radin, N. S. (1981) Arch. Biochem. Biophys. 208, 248-260.
- Radin, N. S. (1984) in Molecular Basis of Lysosomal Storage Disorders, eds. Barranger, J. A & Brady, R. O. (Academic, New York), pp. 93-112.
- Morimoto, S., Kishimoto, Y., Tomich, J., Weiler, S., Ohashi, T., Barranger, J. A., Kretz, K. A. & O'Brien, J. S. (1990) J. Biol. Chem. 265, 1933-1937.
- 12. Conzelmann, E. & Sandhoff, K. (1978) Proc. Natl. Acad. Sci. USA 75, 3979-3992.
- 13. Sandhoff, K., Conzelmann, E., Neufeld, E. F., Kaback, M. M. & Suzuki, K. (1989) in Metabolic Basis of Inherited Disease,

eds. Scriver, C. R., Beaudet, A. L., Sly, W. S. & Valle, D. (McGraw-Hill, New York), pp. 1807-1839.

- 14. Fujibayashi, S. & Wenger, D. A. (1986) Biochim. Biophys. Acta 875, 554-562.
- 15. Fujibayashi, S. & Wenger, D. A. (1986) J. Biol. Chem. 261, 15339-15343.
- 16. O'Brien, J. S., Kretz, K. A., Dewji, N. N., Wenger, D. A., Esch, F. & Fluharty, A. L. (1988) Science 241, 1098-1101.
- Collard, M. W., Sylvester, S. R., Tsuruta, J. K. & Griswold, 17. M. D. (1988) Biochemistry 27, 4557-4564.
- 18. Fürst, W., Machleidt, W. & Sandhoff, K. (1988) Biol. Chem. Hoppe-Seyler 369, 317-328.
- Morimoto, S., Martin, B., Kishimoto, Y. & O'Brien, J. S. 19. (1988) Biochem. Biophys. Res. Commun. 156, 403-410.
- Morimoto, S., Martin, B. M., Yamamoto, Y., Kretz, K. A., 20. O'Brien, J. S. & Kishimoto, Y. (1989) Proc. Natl. Acad. Sci. USA 86, 3389-3393.

- 21. Inui, K. & Wenger, D. A. (1983) J. Clin. Invest. 72, 1622-1628.
- McKusick, V. A. (1988) The Mendelian Inheritance of Man 22. (Johns Hopkins Univ. Press, Baltimore).
- Terry, R. & Weiss, M. (1963) J. Neuropathol. Exp. Neurol. 22, 23. 18-55.
- 24. Samuels, S., Gonatas, N. K. & Weiss, M. (1965) J. Neuropathol. Exp. Neurol. 24, 256-264.
- Purpura, D. P. & Suzuki, K. (1977) Nature (London) 266, 25. 553-563.
- O'Brien, J. S. (1989) in Metabolic Basis of Inherited Disease, 26. eds. Scriver, C. R., Beaudet, A. L., Sly, W. S. & Valle, D. (McGraw-Hill, New York), pp. 1797-1806.
- Walkley, S. U., Blakemore, W. F. & Purpura, D. P. (1981) 27. Acta Neuropathol. (Berlin) 53, 75-86.
- 28.
- Datta, S. C. & Radin, N. S. (1986) Lipids 21, 702-709. Datta, S. C., Snider, R. M. & Radin, N. S. (1986) Biochim. 29. Biophys. Acta 877, 387-398.